Ohno R, Kodera Y, Ogura M, Murase T, Emi N, Okumura M, Morishita Y, Nagura E, Minami S, Morishima Y
Cancer Chemother Pharmacol. 1985;14(1):34-7. doi: 10.1007/BF00552722.
Thirty cases of plasma cell neoplasms (24 multiple myeloma, one plasma cell leukemia, and three primary macroglobulinemia) were treated with two kinds of highly purified alpha-interferons, recombinant human leukocyte interferon (rIFN-alpha A) (16 cases) and human lymphoblastoid interferon (HLBI) (14 cases). Partial remission (PR) was obtained in two of 16 evaluable cases treated with rIFN-alpha A and in two of 12 evaluable cases treated with HLBI. If minor response (MR) was included, responses were observed in seven (31.3%) and six (50%), respectively. Response (PR + MR) was noted in 38% of 21 previously treated patients and 71% of seven previously untreated patients. Side-effects were noted in more than two-thirds of the patients. They included fever, malaise, nausea/anorexia and myelosuppression. Thus, these two kinds of highly purified alpha-interferon were effective in plasma cell neoplasm, producing unequivocal response in 14.3% of the cases without unacceptable side-effects.
30例浆细胞肿瘤患者（24例多发性骨髓瘤、1例浆细胞白血病和3例原发性巨球蛋白血症）接受了两种高度纯化的α干扰素治疗，即重组人白细胞干扰素（rIFN-αA）（16例）和人淋巴母细胞干扰素（HLBI）（14例）。在接受rIFN-αA治疗的16例可评估病例中有2例获得部分缓解（PR），在接受HLBI治疗的12例可评估病例中有2例获得部分缓解。若将微小反应（MR）包括在内，则分别有7例（31.3%）和6例（50%）出现反应。在21例既往接受过治疗的患者中，38%出现反应（PR + MR），在7例既往未接受过治疗的患者中，71%出现反应。超过三分之二的患者出现了副作用。副作用包括发热、不适、恶心/厌食和骨髓抑制。因此，这两种高度纯化的α干扰素对浆细胞肿瘤有效，在14.3%的病例中产生了明确反应，且无不可接受的副作用。
